title: Effect of treatment with rosiglitazone on high-sensitivity cardiac troponin levels among patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  To assess the impact of intermediate-term treatment with rosiglitazone on high-sensitivity cardiac troponin T levels among patients with type 2 diabetes mellitus with or at high risk of coronary artery disease.
  
  
  METHODS
  High-sensitivity cardiac troponin T level was measured at baseline and after 6 months of study treatment in a randomized trial comparing rosiglitazone versus placebo in patients with type 2 diabetes and prevalent cardiovascular disease or multiple cardiovascular disease risk factors. Univariable and multivariable linear regression analyses were performed to assess the effect of rosiglitazone versus placebo on high-sensitivity cardiac troponin T levels.
  
  
  RESULTS
  The study included 150 randomized participants, of whom 106 had paired baseline and end-of-study blood samples for analysis (mean age: 56 ± 8 years, 42% women; 8.8 years average type 2 diabetes duration; mean haemoglobin A1c of 7.5). Almost all study participants (93%) had detectable high-sensitivity cardiac troponin T (⩾ 3 ng/L) at baseline, including 23% with high-sensitivity cardiac troponin T levels exceeding the threshold commonly used to diagnose myocardial infarction (⩾ 14 ng/L). Change in high-sensitivity cardiac troponin T levels from baseline to follow-up was not significantly different between rosiglitazone and placebo groups (p = 0.316).
  
  
  CONCLUSIONS
  Rosiglitazone did not impact high-sensitivity cardiac troponin T levels, adding to the growing body of literature suggesting that the incremental heart failure risk associated with rosiglitazone is not mediated by direct myocardial injury.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Usman I
authors.initials: UI
authors.lastname: Salahuddin
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Ambarish
authors.initials: A
authors.lastname: Pandey
authors.affiliation: Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Colby R
authors.initials: CR
authors.lastname: Ayers
authors.affiliation: Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA.
authors.forename: Raphael
authors.initials: R
authors.lastname: See
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Ian J
authors.initials: IJ
authors.lastname: Neeland
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: M Odette
authors.initials: MO
authors.lastname: Gore
authors.affiliation: Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.
authors.forename: D Bennett
authors.initials: DB
authors.lastname: Grinsfelder
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Shuaib M
authors.initials: SM
authors.lastname: Abdullah
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Amit
authors.initials: A
authors.lastname: Khera
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
authors.affiliation: Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA Darren.McGuire@UTSouthwestern.edu.
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
mesh_terms: D000328:Adult; D000368:Aged; D003324:Coronary Artery Disease / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D014336:Troponin / Q000097:blood*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014336:Troponin; D000077154:Rosiglitazone
keywords: Rosiglitazone; cardiovascular disease; diabetes mellitus; high-sensitivity cardiac troponin